// App-Quantinova.ai

2115 : Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study

Researchers

Presenter

  • Laura Coates

Principal Investigators

  • Julio Ramírez

  • Dennis McGonagle

  • Sibel Aydin

  • Miriam Zimmermann

  • Francois Nantel

  • May Shawi

  • Emmanouil Rampakakis

  • Peter Nash

  • Philip J Mease

Medical Centers

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

  • Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain

  • University of Leeds, Leeds, United Kingdom

  • University of Ottawa, and Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Janssen, Scientific Affairs, LLC, Zug, Switzerland

  • Nantel MedSci Consult, Montréal, QC, Canada

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada

  • School of Medicine, Griffith University, QLD, Australia, Brisbane, Australia

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

Locations

  • United Kingdom

  • Spain

  • Canada

  • Switzerland

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • C reactive protein

  • Malondialdehyde

  • Tumor necrosis factor

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved